KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Acquires 73,649 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par bought 73,649 shares of the stock in a transaction on Friday, February 7th. The shares were acquired at an average price of $9.29 per share, with a total value of $684,199.21. Following the purchase, the insider now owns 5,086,445 shares of the company’s stock, valued at $47,253,074.05. The trade was a 1.47 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 10th, Venrock Healthcare Capital Par purchased 4,137 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average price of $9.14 per share, with a total value of $37,812.18.
• On Monday, February 3rd, Venrock Healthcare Capital Par purchased 14,562 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average price of $9.22 per share, with a total value of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par purchased 43,707 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average price of $8.76 per share, with a total value of $382,873.32.

KalVista Pharmaceuticals Trading Up 0.9 %

NASDAQ:KALV opened at $9.27 on Wednesday. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $16.88. The company has a 50-day moving average of $8.75 and a 200-day moving average of $10.58. The firm has a market cap of $458.12 million, a price-to-earnings ratio of -2.55 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.01. On average, research analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several large investors have recently made changes to their positions in KALV. The Manufacturers Life Insurance Company boosted its position in shares of KalVista Pharmaceuticals by 27.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after purchasing an additional 3,314 shares in the last quarter. SG Americas Securities LLC purchased a new stake in KalVista Pharmaceuticals during the third quarter valued at about $153,000. China Universal Asset Management Co. Ltd. lifted its stake in KalVista Pharmaceuticals by 67.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after buying an additional 3,328 shares in the last quarter. Emerald Mutual Fund Advisers Trust lifted its stake in KalVista Pharmaceuticals by 23.0% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock valued at $7,538,000 after buying an additional 121,615 shares in the last quarter. Finally, Emerald Advisers LLC lifted its stake in KalVista Pharmaceuticals by 29.8% during the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after buying an additional 192,091 shares in the last quarter.

Analysts Set New Price Targets

KALV has been the subject of several recent research reports. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Bank of America started coverage on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price for the company. TD Cowen started coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 target price for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, KalVista Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).